A research trial in Guinea-Bissau has been approved to withhold hepatitis B vaccinations from some newborns, raising ethical concerns. The study, backed by Danish researchers, aims to enroll 14,000 infants, administering the vaccine to half while withholding it from the others for six weeks. This trial is part of a broader agenda associated with Robert F. Kennedy Jr., a known vaccine opponent.
The approval comes despite significant ethical debates, as critics argue that the trial exploits vulnerable populations. The study's design has changed to include maternal hepatitis B testing, but concerns remain about the risks posed to infants who may contract the virus during the trial period.
Watch for potential backlash from global health organizations as the trial progresses. The ethical implications could lead to increased scrutiny on similar studies in developing nations. Stakeholders should monitor the outcomes closely, especially regarding infant health impacts.